Weight Loss and the Renin-Angiotensin-Aldosterone System
By S. Engeli, J. Böhnke, K. Gorzelniak, J. Janke, P. Schling, M. Bader, F. Luft, Arya M. Sharma. HYPERTENSION, 2005
608 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/cae59a7467dcd116c01b94b2632a869b56939237
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. (2008, background): “ference is associated with reduced activity of all RAS components and accompanied with a 7 mmHg decrease in blood pressure.(77) Remarkably, treatment with RAS inhibitors prevents or delays the development of type 2 diabetes.”
- A Comprehensive Review on Metabolic Syndrome (2014, background): “A simple 5%weight reduction in obese women lowered the systolic blood pressure by 7mmHg and was associated with the decreased levels of angiotensinogen (−27%), renin (−43%), angiotensin-converting enzyme (−12%), aldosterone (−31%), and angiotensinogen expression in adipocytes (−20%) [196].”
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus (2014, background): “40 Thus, our results suggest that several mechanisms may underlie the antihypertensive effects of SGlT2 inhibitors in humans.”
- Activation of the peripheral endocannabinoid system in human obesity. (2005, methodology): “Ambulatory blood pressure and blood lipid measurements were performed by standard procedures (21,22).”
- Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies (2015, background): “A decrease in body weight reduces the expression of WAT angiotensinogen expression and is thought to contribute to the concomitant fall in blood pressure.(279) Various epidemiological studies demonstrate that reduced adiponectin levels correlate with increased risk of CVD in obese individuals.”